TD Cowen analyst Dan Brennan raised the firm’s price target on Danaher to $280 from $265 and keeps an Outperform rating on the shares. The firm said the market viewed the bioprocess guide as quite conservative in addition to a broadly de-risked outlook across the rest of the company, while the 2024 margin/ EPS outlook was solid.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DHR:
- Danaher Corporation Reports Earnings: Did it Beat Estimate Forecasts?
- Danaher (NYSE:DHR) Drops on Dismal Q4 Numbers
- Danaher sees FY24 revenue down low-single digits, consensus $24.05B
- Danaher sees Q1 revenue down high-single digits, consensus $5.73B
- Danaher Reports Fourth Quarter and Full Year 2023 Results
